Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells

Biochemical and Biophysical Research Communications

Volumn 305, Issue 3, 2003, Pages 462-469

  Yang, Lin ^a   Wang, Liang ^a   Lin, Hui Kuan ^a   Kan, Pu Yeh ^a   Xie, Shaozhen ^a   Tsai, Meng Yin ^a   Wang, Peng Hui ^a   Chen, Yen Ta ^a   Chang, Chawnshang ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

AR; IL 6; MAPK; PI3K; STAT3; Transactivation

Indexed keywords

ANDROGEN RECEPTOR; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; STAT3 PROTEIN;

ARTICLE; CANCER CELL; CANCER GROWTH; CONTROLLED STUDY; ENZYME ASSAY; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TRANSACTIVATION; WESTERN BLOTTING;

EID: 0037564511     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(03)00792-7     Document Type: Article

References (31)

1. Siegsmund M.J., Yamazaki H., Pastan I. Interleukin 6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia. J. Urol. 151:1994;1396-1399.
2. Chung T.D., Yu J.J., Spiotto M.T., Bartkowski M., Simons J.W. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate. 38:1999;199-207.
3. Okamoto M., Webber M.M., Quader S., Oyasu R. Interleukin-6 and epidermal growth factor promote anchorage-independent growth of immortalized human prostatic epithelial cells treated with N-methyl-N-nitrosourea. Prostate. 35:1998;255-262.
4. Twillie D.A., Eisenberger M.A., Carducci M.A., Hseih W.S., Kim W.Y., Simons J.W. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology. 45:1995;542-549.
5. Drachenberg D.E., Elgamal A.A., Rowbotham R., Peterson M., Murphy G.P. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate. 41:1999;127-133.
6. Mori S., Murakami-Mori K., Bonavida B. Interleukin-6 induces G1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells. Biochem. Biophys. Res. Commun. 257:1999;609-614.
7. Hobisch A., Eder I.E., Putz T., Horninger W., Bartsch G., Klocker H., Culig Z. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res. 58:1998;4640-4645.
8. Lou W., Ni Z., Dyer K., Tweardy D.J., Gao A.C. Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate. 42:2000;239-242.
9. Qiu Y., Ravi L., Kung H.J. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature. 393:1998;83-85.
10. Chang C.S., Kokontis J., Liao S.T. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science. 240:1988;324-326.
11. Yeh S., Chang H.C., Miyamoto H., Takatera H., Rahman M., Kang H.Y., Thin T.H., Lin H.K., Chang C. Differential induction of the androgen receptor transcriptional activity by selective androgen receptor coactivators. Keio. J. Med. 48:1999;87-92.
12. Kang H.Y., Yeh S., Fujimoto N., Chang C. Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor. J. Biol. Chem. 274:1999;8570-8576.
13. Fujimoto N., Yeh S., Kang H.Y., Inui S., Chang H.C., Mizokami A., Chang C. Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate. J. Biol. Chem. 274:1999;8316-8321.
14. Chang C., Saltzman A., Yeh S., Young W., Keller E., Lee H.J., Wang C., Mizokami A. Androgen receptor: an overview. Crit. Rev. Eukaryot. Gene Expr. 5:1995;97-125.
15. Hsiao P.W., Thin T.H., Lin D.L., Chang C. Differential regulation of testosterone vs. 5α-dihydrotestosterone by selective androgen response elements. Mol. Cell. Biochem. 206:2000;169-175.
16. Culig Z., Hobisch A., Cronauer M.V., Radmayr C., Trapman J., Hittmair A., Bartsch G., Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 54:1994;5474-5478.
17. Craft N., Shostak Y., Carey M., Sawyers C.L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med. 5:1999;280-285.
18. Lin D.L., Whitney M.C., Yao Z., Keller E.T. Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. Clin. Cancer Res. 7:2001;1773-1781.
19. Ueda T., Bruchovsky N., Sadar M.D. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J. Biol. Chem. 277:2002;7076-7085.
20. Ueda T., Mawji N.R., Bruchovsky N., Sadar M.D. Ligand-independent activation of the androgen receptor by IL-6 and the role of the coactivator SRC-1 in prostate cancer cells. J. Biol. Chem. 5:2002;5.
21. ′ -kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells Cancer Res. 59:1999;2891-2897.
22. Tezuka-Takahashi M., Hibi M., Fujitani Y., Fukada T., Yamaguchi T., Hirano T. Tec tyrosine kinase links the cytokine receptors to PI-3 kinase probably through JAK. Oncogene. 14:1997;2273-2282.
23. ′ -kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells Proc. Natl. Acad. Sci. USA. 95:1998;3644-3649.
24. Chung T.D., Yu J.J., Kong T.A., Spiotto M.T., Lin J.M. Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines. Prostate. 42:2000;1-7.
25. Crowder R.J., Freeman R.S. Phosphatidylinositol 3-kinase and Akt protein kinase are necessary and sufficient for the survival of nerve growth factor-dependent sympathetic neurons. J. Neurosci. 18:1998;2933-2943.
26. Caldenhoven E., van Dijk T.B., Solari R., Armstrong J., Raaijmakers J.A., Lammers J.W., Koenderman L., de Groot R.P. STAT3β, a splice variant of transcription factor STAT3, is a dominant negative regulator of transcription. J. Biol. Chem. 271:1996;13221-13227.
27. Huang C., Schmid P.C., Ma W.Y., Schmid H.H., Dong Z. Phosphatidylinositol-3 kinase is necessary for 12-O-tetradecanoylphorbol-13-acetate-induced cell transformation and activated protein 1 activation. J. Biol. Chem. 272:1997;4187-4194.
28. Siegall C.B., Schwab G., Nordan R.P., FitzGerald D.J., Pastan I. Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells. Cancer Res. 50:1990;7786-7788.
29. Giri D., Ozen M., Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am. J. Pathol. 159:2001;2159-2165.
30. Chen T., Wang L.H., Farrar W.L. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res. 60:2000;2132-2135.
31. Debes J.D., Schmidt L.J., Huang H., Tindall D.J. P300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res. 62:2002;5632-5636.